US › Healthcare

PDS Biotechnology Corp (PDSB)

US · Healthcare · Biotechnology

$0.84-14.98%

Last close · 2026-09-17

Latest quarter · ended 2026-06-30

Revenue

Net profit

$-9.8M

EPS

$-0.18

EPS estimate

$-0.13

EPS came in at -0.18 against a street estimate of -0.13 — a miss of 38.5%.

Key statistics

Market cap

$17.6M

Forward P/E

0.0

P/B

3.47

Book value

$-0.06

EPS (TTM)

$-0.69

52-week high

$1.55

52-week low

$0.20

50-day MA

$0.53

200-day MA

$0.81

Beta

1.45

Analyst view

Analysts rate PDS Biotechnology Corp a strong buy (3 buy, 0 hold, 0 sell out of 3) with an average price target of $4.75.

Shareholding

Insiders

1.51%

Institutions

13.86%

Largest institutional holders

Fund	Stake
Vanguard Capital Management, LLC	2.91%
Geode Capital Management, LLC	1.18%
BlackRock Inc	0.99%
Militia Capital Management, LLC	0.59%
Vanguard Fiduciary Trust Co	0.55%
Blair William & Co	0.54%
Renaissance Technologies Corp	0.39%
Integrys Wealth Advisors LLC	0.34%

See the full picture

Technicals, trade setups with a published hit rate, AI analysis and earnings-call summaries for PDS Biotechnology Corp — free to start.

Google Play App Store

Other Healthcare companies

Eli Lilly and Company Johnson & Johnson AbbVie Inc Merck & Company Inc UnitedHealth Group Incorporated Novartis AG ADR AstraZeneca PLC Thermo Fisher Scientific Inc Amgen Inc Novo Nordisk A/S Gilead Sciences Inc Abbott Laboratories

Data updated 2026-09-18.